• Z-DEVD-FMK in DR5 Apoptosis Assays

  2026-08-11

  Z-DEVD-FMK is more than a caspase-3 inhibitor: its activity across executioner caspases and calpain creates a powerful, but nuanced, perturbation tool. This article shows how to apply it to DR5–PD-L1 apoptosis assays without confusing pathway blockade with mechanistic proof.

• Cabozantinib (XL184) in RCC Signaling Research

  2026-08-11

  Cabozantinib, also called XL184, is a multi-target receptor tyrosine kinase inhibitor with VEGFR2, MET, RET, and AXL activity. Evidence from kinase assays, tumor models, and renal cell carcinoma phosphoproteomics supports its use for studying angiogenesis, tumor signaling, and chronic drug adaptation.

• Oseltamivir acid: Influenza Research Workflows

  2026-08-10

  Build reproducible neuraminidase, viral replication, and oncology assays with Oseltamivir acid, while controlling solubility, vehicle effects, and resistance-related variability. This guide translates product-specific evidence and a humanized-mouse pharmacokinetic study into practical assay decisions for influenza antiviral research.

• ECL Chemiluminescent Substrate Detection Kit Guide

  2026-08-09

  The ECL Chemiluminescent Substrate Detection Kit (Enhanced) supports sensitive HRP-based western blot chemiluminescence detection when weak protein bands, background, or limited sample are concerns. It is intended primarily for HRP-mediated protein immunodetection and should not be assumed to perform equivalently with non-HRP labels, ELISA, tissue imaging, or other assay formats without local validation.

• Targeted mRNA Nanoparticles and BBB Repair After Stroke

  2026-08-08

  This ACS Nano study developed M2 microglia-targeting lipid nanoparticles that deliver interleukin-10 mRNA to ischemic brain tissue after stroke. In mouse models, the treatment reinforced anti-inflammatory microglial polarization, reduced blood–brain barrier disruption and neuronal apoptosis, and improved neurological outcomes, while suggesting a poststroke treatment window extending to at least 72 hours.

• Salmonella Haem, SirM, and Macrophage Phagocytosis

  2026-08-07

  A recent Nature Microbiology study identifies SirM as a Salmonella methyltransferase that modifies HemL, increases bacterial haem synthesis, and suppresses macrophage phagocytosis through a TLR4-dependent effect on Cdc42. The work reframes pathogen-derived haem as an active immune-evasion factor, not merely an iron source, and connects this mechanism to macrophage death, mouse virulence, and competition with intestinal commensals.

• Anlotinib Hydrochloride: Next-Gen Anti-Angiogenic Strategies

  2026-08-07

  Explore the mechanistic depth and translational promise of Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor that redefines anti-angiogenic research. From endothelial cell migration inhibition to robust in vivo activity, this article delivers actionable insights, protocol guidance, and a strategic vision for cancer researchers seeking to bridge lab discoveries with clinical impact.

• Firefly Luciferase mRNA (5-moUTP): Innovations in Reporter G

  2026-08-06

  Explore how Firefly Luciferase mRNA (5-moUTP) optimizes bioluminescent reporter gene assays by integrating next-generation modifications for stability, immunogenicity, and translational efficiency. This article reveals pivotal scientific advances and practical guidance for maximizing assay reliability.

• Cyclic di-GMP: Applied Protocols for Biofilm & Immunity Rese

  2026-08-06

  Harnessing cyclic di-GMP as an intracellular second messenger unlocks novel methods for regulating biofilm persistence and activating innate immunity. Recent breakthroughs reveal its dual role as an antitoxin and STING pathway agonist, making it indispensable for both infection biology and cancer immunotherapy studies.

• Toremifene: A Second-Generation SERM for Prostate Cancer Res

  2026-08-05

  Toremifene is a selective estrogen-receptor modulator with verified efficacy in inhibiting hormone-dependent prostate cancer cell growth. Its robust in vitro IC50 profile and compatibility with advanced models make it a valuable tool in estrogen receptor signaling pathway studies. APExBIO supplies Toremifene (SKU A3884) at 98% purity for research use.

• Gut-Brain Cholinergic Signaling in Microbiota-Mediated Seizu

  2026-08-05

  Jia et al. reveal that Bacteroides fragilis suppresses seizures via enhanced gut-brain cholinergic signaling, mediated by activation of colonic ChAT+ cells and vagal pathways. Their multi-model approach, including clinical validation, points to the gut microbiota's role in modulating epilepsy and highlights mechanistic paths for translational interventions.

• X-Gal (A2539): Data-Driven Solutions for Reliable β-Gal Assa

  2026-08-04

  This expert article addresses practical laboratory challenges in β-galactosidase assays and blue-white screening, focusing on how X-Gal (SKU A2539) from APExBIO delivers reproducibility and data-backed reliability. Drawing on scenario-based Q&A and recent literature, it equips researchers with evidence-based insights for optimizing molecular cloning and recombinant DNA workflows.

• NET-DNA Impairs ILC3-Mediated Intestinal Repair via CCDC25

  2026-08-04

  This study uncovers how DNA from neutrophil extracellular traps (NETs) inhibits intestinal epithelial repair in ulcerative colitis by suppressing IL-22 secretion from group 3 innate lymphoid cells (ILC3s) through the CCDC25 receptor. These findings highlight a novel mechanistic link between NETs and impaired mucosal healing, offering new targets for therapeutic intervention and experimental modeling in mucosal immunology.

• Ganetespib (STA-9090): Advanced Applications in Cancer Resea

  2026-08-03

  Ganetespib (STA-9090) redefines Hsp90 inhibition with unmatched selectivity and potency, enabling high-fidelity tumor growth inhibition in both cellular and animal models. Its robust performance, unique triazolone scaffold, and proven integration with cell death pathway assays make it indispensable for advanced cancer research workflows.

• Brassinolide in Plant and Cancer Research: Protocols & Innov

  2026-08-03

  Brassinolide (24-Epibrassinolide) empowers both plant growth regulation and cancer apoptosis research with precise, reproducible workflows. This article details advanced protocols, troubleshooting insights, and translational applications, revealing how APExBIO’s Brassinolide bridges plant and biomedical domains for impactful experimentation.

16907 records 1/1128 page Next 12345 下5页 Last page